Switch theme
Sign up to access all valuation multiples
Lupin Ltd is a specialty and generic drug manufacturing company. The company produces, develops, and markets branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) globally. It has a presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, Central Nervous System, GastroIntestinal, and other drug therapy segments. The operations of the company are limited to the segments, namely pharmaceuticals which derives key revenue, and others. It also maintains a pipeline in high-barrier markets such as Inhalation, Biosimilars, and Complex Injectables. The vast majority of the company's sales are generated in the United States, followed by India, and other countries.
1983
20.1K+
LTM Revenue $2.7B
LTM EBITDA $643M
$10.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Lupin has a last 12-month revenue (LTM) of $2.7B and a last 12-month EBITDA of $643M.
In the most recent fiscal year, Lupin achieved revenue of $2.6B and an EBITDA of $642M.
Lupin expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Lupin valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.7B | XXX | $2.6B | XXX | XXX | XXX |
| Gross Profit | $1.9B | XXX | $1.8B | XXX | XXX | XXX |
| Gross Margin | 70% | XXX | 69% | XXX | XXX | XXX |
| EBITDA | $643M | XXX | $642M | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 25% | XXX | XXX | XXX |
| EBIT | $513M | XXX | $521M | XXX | XXX | XXX |
| EBIT Margin | 19% | XXX | 20% | XXX | XXX | XXX |
| Net Profit | $408M | XXX | $384M | XXX | XXX | XXX |
| Net Margin | 15% | XXX | 15% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $414M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Lupin's stock price is INR 1958 (or $23).
Lupin has current market cap of INR 894B (or $10.5B), and EV of INR 904B (or $10.6B).
See Lupin trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $10.6B | $10.5B | XXX | XXX | XXX | XXX | $0.90 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Lupin has market cap of $10.5B and EV of $10.6B.
Lupin's trades at 4.2x EV/Revenue multiple, and 17.8x EV/EBITDA.
Equity research analysts estimate Lupin's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Lupin has a P/E ratio of 25.7x.
See valuation multiples for Lupin and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $10.5B | XXX | $10.5B | XXX | XXX | XXX |
| EV (current) | $10.6B | XXX | $10.6B | XXX | XXX | XXX |
| EV/Revenue | 3.9x | XXX | 4.2x | XXX | XXX | XXX |
| EV/EBITDA | 16.5x | XXX | 17.8x | XXX | XXX | XXX |
| EV/EBIT | 20.6x | XXX | 22.4x | XXX | XXX | XXX |
| EV/Gross Profit | 5.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 25.7x | XXX | 30.4x | XXX | XXX | XXX |
| EV/FCF | 78.2x | XXX | 54.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialLupin's last 12 month revenue growth is 11%
Lupin's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Lupin's rule of 40 is 35% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Lupin's rule of X is 51% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Lupin and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 24% | XXX | XXX | XXX |
| EBITDA Growth | 15% | XXX | 11% | XXX | XXX | XXX |
| Rule of 40 | 35% | XXX | 35% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 51% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 49% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Lupin acquired XXX companies to date.
Last acquisition by Lupin was XXXXXXXX, XXXXX XXXXX XXXXXX . Lupin acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Lupin founded? | Lupin was founded in 1983. |
| Where is Lupin headquartered? | Lupin is headquartered in India. |
| How many employees does Lupin have? | As of today, Lupin has 20.1K+ employees. |
| Who is the CEO of Lupin? | Lupin's CEO is Ms. Vinita D. Gupta. |
| Is Lupin publicy listed? | Yes, Lupin is a public company listed on BOM. |
| What is the stock symbol of Lupin? | Lupin trades under 500257 ticker. |
| When did Lupin go public? | Lupin went public in 1995. |
| Who are competitors of Lupin? | Similar companies to Lupin include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Lupin? | Lupin's current market cap is $10.5B |
| What is the current revenue of Lupin? | Lupin's last 12 months revenue is $2.7B. |
| What is the current revenue growth of Lupin? | Lupin revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of Lupin? | Current revenue multiple of Lupin is 3.9x. |
| Is Lupin profitable? | Yes, Lupin is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Lupin? | Lupin's last 12 months EBITDA is $643M. |
| What is Lupin's EBITDA margin? | Lupin's last 12 months EBITDA margin is 24%. |
| What is the current EV/EBITDA multiple of Lupin? | Current EBITDA multiple of Lupin is 16.5x. |
| What is the current FCF of Lupin? | Lupin's last 12 months FCF is $135M. |
| What is Lupin's FCF margin? | Lupin's last 12 months FCF margin is 5%. |
| What is the current EV/FCF multiple of Lupin? | Current FCF multiple of Lupin is 78.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
